Myeloid Growth Factors, Version 1.2018

This is a clinical practice guideline for adults with solid tumours and non-myeloid malignancies who are receiving myelosuppressive chemotherapy. The guideline examines the use of myeloid growth factors (MGFs) in these patients as a method for reducing the incidence of neutropenia. Topics of interest include the benefits and risks of MGFs, as well as their use in prophylactic, therapeutic, and post-transplant settings.